Clinical Trial Record

Return to Clinical Trials

Shwachman-Diamond Syndrome Global Patient Survey and Partnering Platform


2024-02-07


2088-12


2088-12


8000

Study Overview

Shwachman-Diamond Syndrome Global Patient Survey and Partnering Platform

The Shwachman-Diamond Syndrome Global Patient Survey and Collaboration Program (SDS-GPS) is an opportunity for patients and their families - from anywhere in the world - to share their experience living with SDS via a safe, secure, and convenient online platform, to * expand the understanding of SDS * improve the lives of people with SDS, and * accelerate the development of new therapies and cures for SDS. By joining, participants will receive early access to relevant information about new clinical trials and other research opportunities (such as clinical registries) based on their profile, accelerating research and increasing clinical trial impact and recruitment success. The platform, consent forms, and surveys are available in five languages: English, Spanish, French, German, and Italian. More languages to come.

What is SDS-GPS? The Shwachman-Diamond Syndrome Global Patient Survey and Collaboration Program (SDS-GPS) is an opportunity for patients and their families - from anywhere in the world - to share their experience living with SDS via a safe, secure, and convenient online platform, with the goal of * expanding the understanding of SDS and related conditions * improving the lives of people with SDS and related conditions, and * accelerating the development of new therapies and cures for SDS. SDS-GPS was created for the patients, by the patients, with thoughtful input from patients, families, advocates, caregivers, researchers, clinicians, and regulators. Participants will be part of a global community that cares, turns hope into action, and drives research. Participants' experience - whether it falls in the mild or severe end of the spectrum - matters. Their voice counts. How can patients' stories help drive therapies and cures? Participants' stories help paint a more complete picture of what SDS is and how it impacts the people living with it. Their participation helps build a strong, engaged community, which is critical to drive progress. Without patients and their families, research cannot advance. The investigators (the SDS-GPS team at the SDS Alliance) use participants' de-identified aggregate survey responses and other data they share to develop a deeper understanding of the unmet needs of the community. The investigators use the insights to * Prioritize research, educational resources, and community programming * Promote data and knowledge sharing via collaborations, publications, conference presentations, and other communication channels * Provide participants with information about relevant research opportunities (such as the SDS Registry and other natural history studies), clinical trials, educational resources, and community support connections. What aspects of their story can participants share through SDS-GPS? Surveys on the SDS-GPS Program Platform are designed to be quick and easy, without the need to have to look up any details from medical records. They can save their progress and come back anytime. Survey topics include: * Socio-demographics * Medical history and diagnostics * Treatment and disease progression * Management of and access to care * Quality of life How does SDS-GPS work? * Sign up for a free SDS-GPS account and enter a little bit about the participant. Enrolling and participating takes little time, and they can come back later to update any information. * Answer surveys from the comfort of their home at any time that works for them. * Privacy and security are protected to the highest standard. * Move research forward without any clinic visits or virtual appointments. With participants' consent, the investigators publish and share de-identified data (your survey responses) with approved researchers to support research to benefit the SDS community. The information participants provide through easy surveys is structured and coded behind the scenes, to be usable for high-quality, impactful research. * Keep track of the participants' medical appointments, medications, and symptoms via their SDS-GPS account, and have all the information at their fingertips whenever and wherever they need it. * Share any information participants like with their care team. Participants retain full control over access. The platform, consent forms, and surveys are available in five languages: English, Spanish, French, German, and Italian. More languages to come.

  • Shwachman-Diamond Syndrome
  • SDS
  • IBMF
  • Congenital Neutropenia
  • Heme Malignancy
  • Shwachman Syndrome
  • Inherited Bone Marrow Failure
  • Exocrine Pancreatic Insufficiency
  • WHIM
  • ELANE
  • SBDS Gene Mutation
  • EFL1 Gene Mutation
  • DNAJC21 Gene Mutation
  • SRP54 Gene Mutation
  • Inherited Cancer Syndrome
  • Inherited Cancer-Predisposing Syndrome
  • Neutropenia, Severe Chronic
  • Neutropenia Other
  • Neutropenia Chronic Benign
  • Ribosome Alteration
  • Ribosomopathy
  • Immune Deficiency
  • Inherited BMF Syndrome
  • Inherited Immunodeficiency Diseases
  • Cognitive Delay, Mild
  • Myelodysplastic Syndromes
  • Pancytopenia
    • NB300118

    Study Record Dates

    These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

    Study Registration Dates Results Reporting Dates Study Record Updates

    2024-07-20  

    N/A  

    2025-05-23  

    2025-05-23  

    N/A  

    2025-05-31  

    2025-05-31  

    N/A  

    2025-05  

    Study Plan

    This section provides details of the study plan, including how the study is designed and what the study is measuring.

    Design Details

    Primary Purpose:
    N/A


    Allocation:
    N/A


    Interventional Model:
    N/A


    Masking:
    N/A


    Arms and Interventions

    Participant Group/ArmIntervention/Treatment
    Primary Outcome MeasuresMeasure DescriptionTime Frame
    Patient (or caregiver) reported symptoms over timePatients report symptoms via surveys, grouped by organ system.At baseline and every 12 months, prospectively.
    Genetics report uploaded by patient (or caregiver)Clinical genetics reports are uploaded by the patient (or caregiver) and curated by study staff to confirm a genetic diagnosis, understand variants, and assess the use of appropriate genetic testing methodologies.Through study completion when the genetics report is available.
    Quality of life measures via PROMIS surveysPROMIS surveys in various domains, such as fatigue, pain, anxiety, and depression, are administered as surveys and scored with the standard PROMIS scoring methods. Specific PROMIS measures to include: v1.0 Anxiety 8a short form v1.0 Depression 8a short form v1.0 Pain Interference 6a short form v2.0 Cognitive Function 8a short form v1.0 Self-Efficacy for Managing Chronic Conditions: Manage Daily Activities 8a short form v1.0 - Self-Efficacy for Managing Symptoms 8a v2.0 Satisfaction Social Roles and Activities 8a short form v2.0 Ability to Part Social Roles and Activities 8a short form v2.0 Social Isolation 8a short form v1.0 Fatigue 13a short form (FACIT-Fatigue) v3.0 PP: Depressive Symptoms 6a short form v3.0 PP: Fatigue 10a short form v3.0 PP: Mobility 7a short form v3.0 PP: Pain Interference 8a short form v1.0 PP: Cognitive Function 7a short formThrough study completion, an average of 2-4 times per year.
    Patient reported burden of disease and treatment outcomesPatients fill out surveys to report on disease burden (such as number and duration of hospitalizations), treatment burden (such as surveillance), and treatment outcomes (such as HSC transplant outcomes)At baseline and every 12 months, prospectively.
    Secondary Outcome MeasuresMeasure DescriptionTime Frame

    Contacts and Locations

    This section provides the contact details for those conducting the study, and information on where this study is being conducted.

    Study Contact

    Name: Eszter Hars, Ph.D.

    Phone Number: 6173291838

    Email: ehars@sdsalliance.org

    Study Contact Backup

    Name: SDS-GPS Program Team

    Phone Number: 6173291838

    Email: gps@sdsalliance.org

    Participation Criteria

    Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

    Ages Eligible for Study:
    ALL

    Sexes Eligible for Study:

    Accepts Healthy Volunteers:

      Inclusion Criteria:
      The Program invites patients of all ages who have a confirmed diagnosis of the below, using established diagnostic guidelines, plus their parents/caregivers.

    • Patients with a confirmed Shwachman-Diamond Syndrome (SDS) diagnosis, including a genetic or clinical diagnosis. The initial focus will be on patients with a genetic diagnosis of SDS based on biallelic mutations in SBDS or EFL1.
    • Patients with a confirmed diagnosis of an SDS-like syndrome (e.g. due to mutations in DNAJC21, SRP54, or other genes that may be associated with an SDS-like syndrome in the future).
    • Patients with other heritable hematological malignancy disorders (such as RUNX1-FPD, Fanconi Anemia) and/or congenital neutropenias (such as ELANE neutropenia) are also eligible for inclusion.
    • Caregivers, parents, and close relatives of all patients above, including of patients alive or deceased.

    • Exclusion Criteria:
      ● People who do not meet the above criteria.

    Collaborators and Investigators

    This is where you will find people and organizations involved with this study.

    Publications

    The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

    General Publications

    No publications available